Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Martinez-Sanz 2016 Eur J Med Chem

From Bioblast
Publications in the MiPMap
Martínez-Sanz FJ, Lajarín-Cuesta R, González-Lafuente L, Moreno-Ortega AJ, Punzón E, Cano-Abad MF, de los Ríos C (2016) Neuroprotective profile of pyridothiazepines with blocking activity of the mitochondrial Na+/Ca2+ exchanger. Eur J Med Chem 109:114-23.

» PMID: 26774037

Martinez-Sanz FJ, Lajarin-Cuesta R, Gonzalez-Lafuente L, Moreno-Ortega AJ, Punzon E, Cano-Abad MF, de los Rios C (2016) Eur J Med Chem

Abstract: The mitochondrial Na+/Ca2+ exchanger plays an important role in the control of cytosolic Ca2+ cycling in excitable cells, essential for the regulation of a plethora of Ca2+-dependent physio-pathological events, such as apoptosis in the presence of a Ca2+ overload. There are very few pharmacological tools available to study both physiological and pathological implications of the mitochondrial Na+/Ca2+ exchanger, where the benzothiazepine CGP37157 is the best-known ligand, used since the 1980s. However, it is not an efficient blocker and lacks of selectivity, as also blocks several other cellular Ca2+ transporters. Moreover, CGP37157 is a very lipophilic drug, showing very poor water solubility, what has hindered its therapeutic use. Attempting to improve its pharmacokinetic profile as well as its potency and selectivity, we herein describe the synthesis of new CGP37157 analogs, where the benzene-fused ring has been replaced by a pyridine. On top of a better water solubility and lower log P value, some of these new pyridothiazepine derivatives also presented a higher capacity to regulate the mitochondrial Ca2+ clearance, while keeping the neuroprotective properties presented in the head compound CGP37157.

Copyright © 2015 Elsevier Masson SAS. All rights reserved. Keywords: CGP37157, Mitochondria, Mitochondrial NaNa+/Ca2+ exchanger, Neurodegeneration, Neuroprotection, Pyridothiazepines


Labels: